Study of ASKG915 for Advanced Solid Tumors
This study is looking at a new treatment called ASKG915 for people with advanced solid tumors (cancers that have spread). The study will test ASKG915 by itself and in combination with standard treatments like Paclitaxel + Bevacizumab, Fruquintinib, or Docetaxel. Researchers want to understand how safe ASKG915 is, how well your body handles it, and how it affects your cancer. To join, you must have a cancer that hasn't responded to other treatments or for which there are no standard treatments available, be at least 18 years old, and have a good enough general health status. The main goals are to identify any serious side effects and other adverse events (unwanted effects) that might occur.
- Study design
- This is an interventional study with a planned enrollment of 594 participants. It involves different parts to test ASKG915 alone and in combination with other standard treatments.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Adverse events will be measured from the first dose to 30 days after the last dose.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
At a glance
Conditions
NCT05867420
Where you'd take part
This study runs at 4 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, Chinastudy coordinator listed
Recruiting
Peking University Cancer Hospital
Beijing, Beijing Municipality, Chinastudy coordinator listed
Not yet recruiting
Columbia University Irving Medical Center
New York, New Yorkno site contact published
Recruiting
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvaniano site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Jing Chen, MD · STUDY_DIRECTOR · Ask-Gene Pharma, Inc.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Dose limiting toxicities (DLTs)21days or 28 days
To evaluate the safery of ASKG915 in subjects.
- Adverse events(AEs)From the first dose to 30 days after the last dose
To evaluate the safery of ASKG915 in subjects.